Adding Histidine Tags to Cancer-Killing Peptides Helps Them Enter Tumor Cells

Researchers designed pro-apoptotic peptides with His-tag modifications and EGFR-targeting sequences, then tested them against A-549 non-small cell lung cancer cells. Cell viability was measured using MTT assays, apoptosis was confirmed with TUNEL assays, and cellular uptake was visualized with immunofluorescence microscopy.

Getting cancer-killing peptides inside tumor cells is one of the biggest challenges in peptide drug development. This study shows that a simple chemical modification — adding a histidine tag — can improve cellular uptake of pro-apoptotic peptides without complex targeting systems. While the EGFR-targeting strategy didn't work as hoped, the His-tag finding offers a practical approach to enhancing peptide delivery for cancer therapy.

Peptide-based cancer therapies are gaining momentum, but delivering peptides into cells remains a major bottleneck. This study adds to the evidence that simple chemical modifications can significantly improve peptide uptake. The His-tag approach is inexpensive and easy to implement, making it a practical tool for peptide drug development — even if more sophisticated targeting strategies require further refinement.

This is an in vitro study using a single cancer cell line (A-549). The IC50 values (33–41 µM) are relatively high for drug candidates, which may limit clinical applicability. No animal testing was performed. The EGFR-targeting strategy did not improve efficacy over the non-targeted version, raising questions about the design approach. Selectivity for cancer cells over normal cells was not thoroughly assessed.